This improved understanding of PT2385 metabolism and pharmacokinetics and its correlation with anti-tumor efficacy, subsequently led to the development of the next-generation HIF2α inhibitor PT2977 (MK-6482, subsequently named belzutifan), which displayed decreased glucuronidation, an improved pharmacokinetic profile, and enhanced potency relative to its parent compound [49]. Here, EPAS1 is linked to neoplasm.